Iqvia Holdings Inc.
IQVIA Reports Strong Q1 2026 Financial Results and Raises Guidance
Summary
IQVIA Holdings Inc. reported strong financial results for the first quarter of 2026, with revenue of $4.151 billion, up 8.4% year-over-year. The company's GAAP net income was $274 million, and adjusted EBITDA was $932 million. IQVIA also raised its full-year 2026 guidance for adjusted diluted earnings per share to a range of $12.65 to $12.95. Additionally, the company repurchased $552 million of its common stock during the quarter.
Profitelligence Alerts
Get alerts for IQV
Be first to know when Iqvia Holdings Inc. files with the SEC.
Filing Categories
Advertisement
About Iqvia Holdings Inc.
Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.
Official SEC Documents
Advertisement